Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
As of today (2024-04-19), Supernus Pharmaceuticals's Intrinsic Value: Projected FCF is $35.15. The stock price of Supernus Pharmaceuticals is $29.34. Therefore, Supernus Pharmaceuticals's Price-to-Intrinsic-Value-Projected-FCF of today is 0.8.
The historical rank and industry rank for Supernus Pharmaceuticals's Intrinsic Value: Projected FCF or its related term are showing as below:
SUPN'
s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 0.65 Med: 0.85 Max: 30.06
Current: 0.83
During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Supernus Pharmaceuticals was 30.06. The lowest was 0.65. And the median was 0.85.
SUPN's Price-to-Projected-FCF is ranked better than 79.3% of 599
companies
in the Drug Manufacturers industry
Industry Median: 1.51
vs SUPN: 0.83
Supernus Pharmaceuticals Intrinsic Value: Projected FCF Historical Data
The historical data trend for Supernus Pharmaceuticals's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Supernus Pharmaceuticals Annual Data
Trend
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
Intrinsic Value: Projected FCF
28.68
38.55
43.66
41.01
35.15
Supernus Pharmaceuticals Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
Intrinsic Value: Projected FCF
41.01
38.49
36.55
35.58
35.15
Competitive Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Supernus Pharmaceuticals's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Supernus Pharmaceuticals Price-to-Projected-FCF Distribution
For the Drug Manufacturers industry and Healthcare sector, Supernus Pharmaceuticals's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where Supernus Pharmaceuticals's Price-to-Projected-FCF falls into.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
Supernus Pharmaceuticals's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
29.34
/
35.150705242107
=
0.83
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Supernus Pharmaceuticals Intrinsic Value: Projected FCF Related Terms
Thank you for viewing the detailed overview of Supernus Pharmaceuticals's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Supernus Pharmaceuticals (Supernus Pharmaceuticals) Business Description
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SUPN has been successfully added to your 